SynthesisFrontiers in endocrinology2025
Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Anti-sclerostin antibodies are novel biologics for the treatment of postmenopausal osteoporosis, while their efficacy and safety are yet to be fully understood. The aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of anti-sclerostin antibodies compared to placebo, alendronate, teriparatide and denosumab in the treatment of osteoporosis. Methods: This systematic review and meta-analysis included a total of 10 randomized controlled trials (RCTs),involving 12,384 participants with postmenopausal osteoporosis, comparing anti-sclerostin antibodies with alendronate, teriparatide, denosumab, or placebo in postmenopausal women with osteoporosis. The quality of randomized controlled trials was evaluated by using the Cochrane Collaboration's Randomized Controlled Trial Risk of Bias Assessment Tool, and meta-analysis was performed by using the RevMan software. The primary outcome was the percentage change in bone mineral density(BMD)at 6 and 12 months compared to baseline. Secondary outcomes included the incidence of adverse events and cardiovascular complications. Results: Compared with placebo, alendronate, and teriparatide, anti-sclerostin antibodies significantly increased BMD at the lumbar spine, total hip, and femoral neck at 6 and 12 months. Compared with denosumab, anti-sclerostin antibodies significantly increased lumbar spine bone mineral density at 6 months (MD = 3.68, 95% CI: 0.34-7.01, P = 0.03) and 12 months (MD = 5.20, 95% CI: 3.19-7.21, P < 0.00001). No significant differences in BMD were found at the total hip and femoral neck versus denosumab. Regarding safety, anti-sclerostin antibodies had a lower incidence of adverse events than alendronate (RR = 0.96, 95% CI: 0.93-0.99, P = 0.02) but a higher incidence than teriparatide (RR = 1.13, 95% CI: 1.01-1.25, P = 0.03). There was no significant difference in adverse events compared to placebo (RR = 0.98, 95% CI: 0.96-1, P = 0.1) or denosumab (RR = 2.64, 95% CI: 0.74-9.36, P = 0.13). Importantly, anti-sclerostin antibodies did not significantly increase the risk of cardiovascular complications compared to other treatments (RR = 1.23, 95% CI: 0.92-1.64, P = 0.17). Conclusion: Anti-sclerostin antibodies are effective at increasing BMD, with a pronounced effect on the lumbar spine, and demonstrate a controllable overall risk profile. The study results demonstrate that anti-sclerostin antibodies can be used to treat postmenopausal osteoporosis. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251103597.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.